Concurrent Imatinib and Radiation Therapy for Unresectable and Symptomatic Desmoid Tumors.

about

Concurrent Imatinib and Radiation Therapy for Unresectable and Symptomatic Desmoid Tumors.

Item

http://www.wikidata.org/entity/Q39152035

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Concurrent Imatinib and Radiat ...... nd Symptomatic Desmoid Tumors.

@en

Concurrent Imatinib and Radiat ...... nd Symptomatic Desmoid Tumors.

@nl

type

Item

label

Concurrent Imatinib and Radiat ...... nd Symptomatic Desmoid Tumors.

@en

Concurrent Imatinib and Radiat ...... nd Symptomatic Desmoid Tumors.

@nl

prefLabel

Concurrent Imatinib and Radiat ...... nd Symptomatic Desmoid Tumors.

@en

Concurrent Imatinib and Radiat ...... nd Symptomatic Desmoid Tumors.

@nl

P1476

Concurrent Imatinib and Radiation Therapy for Unresectable and Symptomatic Desmoid Tumors

@en

P2093

Lynn Million

http://www.w3.org/2001/XMLSchema#string

Pejman Ghanouni

http://www.w3.org/2001/XMLSchema#string

Raffi Avedian

http://www.w3.org/2001/XMLSchema#string

P2860

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Is MR-guided High-intensity Focused Ultrasound a Feasible Treatment Modality for Desmoid Tumors?

STRIDE--An integrated standards-based translational research informatics platform.

In vitro effects of imatinib mesylate on radiosensitivity and chemosensitivity of breast cancer cells.

Surgery versus radiation therapy for patients with aggressive fibromatosis or desmoid tumors: A comparative review of 22 articles.

Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up.

Efficacy of imatinib in aggressive fibromatosis: Results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial.

Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor).

Results of a phase II pilot study of moderate dose radiotherapy for inoperable desmoid-type fibromatosis--an EORTC STBSG and ROG study (EORTC 62991-22998).

Imatinib radiosensitizes bladder cancer by targeting homologous recombination.

P304

2316839

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2017/2316839

http://www.w3.org/2001/XMLSchema#string

P478

2017

http://www.w3.org/2001/XMLSchema#string

P50

Christian A Kunder

Everett J Moding

Kristen N Ganjoo

P577

2017-07-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28761389

http://www.w3.org/2001/XMLSchema#string

P921

radiation therapy

P932

5516706

http://www.w3.org/2001/XMLSchema#string